This report describes higher protection against COVID-19 infection and death among people who received an updated booster than people who received a monovalent booster.
This report describes how the median completed COVID-19 vaccinations series among older adults in 2022 was 76%, which is below the WHO goal, especially in middle- and low-income countries.
This report describes how continued monitoring of S-gene target failure and S-gene target presence patterns will likely serve as a useful complement to genomic surveillance of SARS-CoV-2 lineages.
This report describes how a bivalent mRNA booster dose provided additional protection against symptomatic XBB/XBB.1.5 infection for at least the first 3 months after vaccination in persons who had previously received 2–4 monovalent vaccine doses.
This report describes higher rates of pediatric hospitalization and symptomatic illness from influenza among children during the 2022–23 season in Tennessee.
This report describes an investigation of mental and physical health symptoms reported among residents a year after a chemical exposure fire in Winnebago County, Illinois.
This report describes similar early safety findings from the Vaccine Adverse Event Reporting System for bivalent booster vaccination in children aged 5–11 years as the monovalent booster vaccination.
This report describes 2021 data from National Center for Health Interview Survey on the percentage of adults who have ever had hepatitis by age group and sex.
This report describes declines in vaccination coverage reported by the National Immunization Survey–Child among young children born during 2018–2019 living below the federal poverty level and in rural areas.
This report describes overall low COVID-19 vaccination coverage among children and adolescents 5–17 years old and parental intent to vaccinate their child.
This report describes cases of mpox among cisgender women and the use of tecovirimat with no reported adverse reaction to treat four pregnant people with mpox.
This report describes the effectiveness of the updated (bivalent) COVID-19 vaccines for prevention of COVID-19-associated hospitalization among adults ages 65 years or older who did not have a weakened immune system and who were hospitalized with COVID-19-like illness.
This report describes the effectiveness of the updated (bivalent) COVID-19 vaccines for prevention of COVID-19 associated emergency department and urgent care visits and hospitalization among adults ages 18 years or older without a weakened immune system.
This report describes environmental testing on soil and a racoon carcass following a multistate outbreak of melioidosis linked to an aromatherapy room spray.
This report describes a recent finding that mpox incidence among unvaccinated men aged 18–49 years was 10 times as high as vaccinated men who received both JYNNEOS doses.